Late-stage Pipeline Event 2013
The event provided an opportunity to discuss clinical data and development plans for key late-stage compounds in the Roche development pipeline, including lampalizumab (anti-factor D) in dry AMD, etrolizumab in ulcerative colitis and selected oncology compounds.
- Alan Hippe, Chief Financial and IT Officer - Introduction
- Hal Barron, Head of Global Product Development, Chief Medical Officer - Pipeline update
- Karl Mahler, Head of Investor Relations - Moderator
Link to the video webcast replay